- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04709692
Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria
An Open Label Phase 2a Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of (+)-SJ000557733 (SJ733) With or Without Cobicistat in Adult Patients With Acute, Uncomplicated Malaria Over a 42 Day Period
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Loreto
-
Iquitos, Loreto, Peru
- Asociacion Civil Selva Amazonica (ACSA)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, aged 18 to 70 years of age (inclusive) at screening.
- Body weight between 45 kg and 90 kg inclusive
Presence of mono-infection of P. falciparum or P. vivax confirmed by:
- Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,
- Microscopically confirmed parasite infection: 1,000 to 40,000 asexual parasite count/µL blood
- Written informed consent provided by participant, in accordance with local practice. If the participant is unable to write, witnessed consent is permitted according to local ethical considerations.
- Ability to swallow oral medication.
- Ability and willingness to participate and to comply with the study requirements
- Agreement to hospitalization for at least 102 hours and/or until malarial parasites are not detected by microscopy on 2 consecutive occasions.
- Agreement to come back to the hospital on Days 7, 10 or 11, 14, 17 or 18, 21, 24 or 25, 28, 35, and 42.
Women of child-bearing potential, has a negative pregnancy test at screening, and agrees to comply with one of the following during the treatment stage of the study and for a period of 90 days after stopping study drug:
- Use of oral, implantable, or injectable hormonal contraceptive, either combined or progestogen alone used in conjunction with barrier method as defined below.
- Use of an intrauterine device with a documented failure rate of <1% per year.
- Barrier method consisting of either condom or diaphragm.
- Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female.
- Complete abstinence from intercourse for 2 weeks prior to administration of study drug, throughout the study and for a period of 90 days after stopping study drug.
Exclusion Criteria:
- Signs and symptoms of severe/complicated malaria according to the World Health Organization Criteria 2010 (Attachment 1: Definition of Severe Malaria)
- Mixed Plasmodium infection.
- Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study, or severe diarrhea defined as 3 or more watery stools per day.
- Severe malnutrition (defined as the weight-for-height being below -3 standard deviation or less than 70% of median of the NCHS/WHO normalized reference values)
- Presence of a significant medical or psychiatric condition, or any other serious or chronic clinical condition requiring hospitalization, or any other condition that in the opinion of the investigator precludes participation in the study.
- Female patients must not be either lactating or pregnant as demonstrated by a negative serum point-of-care pregnancy test pre-dose (the result of the pre-dose assessment must be confirmed negative prior to dosing).
- Employment under the direct supervision of the investigators or study staff.
Clinically significant alterations to hematologic or clinical chemistry parameters that in the opinion of the investigator precludes participation in the study, including:
- AST/ALT > 3 x upper limit of normal range (ULN) and total bilirubin is normal
- AST/ALT > 2 x ULN and total bilirubin is >1 and <1.5 x ULN and conjugated bilirubin is > 35% of the total bilirubin
- Total bilirubin > 1.5 x ULN
- Serum creatinine levels > 2 x ULN
- Hb level < 8 g/dL
- Platelet level < 50,000/mm3
- Participation in a clinical study of another investigational small molecule within 30 days or investigational biologic within 90 days prior to study enrollment or planning to begin such participation during the study.
Have received any antimalarial treatment (alone or in combination) in the past containing:
- Piperaquine, mefloquine, naphthoquine or sulphadoxine / pyrimethamine within the previous 6 weeks
- Amodiaquine or chloroquine within the previous 4 weeks
- Any artemisinin (artesunate, artemether, arteether or dihydroartemisinin) quinine, halofantrine, lumefantrine and any other anti-malarial treatment or antibiotics with antimalarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin) within the past 14 days
- Any medication from the list of prohibited medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Arm 1 A (cohort 1)
Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
|
Anti-Malarial
Other Names:
|
Other: Arm 1 B (cohort 1)
Combination of 600 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
|
Anti-Malarial
Other Names:
|
Other: Arm 2 A (cohort 2)
600 mg SJ733 administered orally once every day for three consecutive days for patients with P.vivax
|
Anti-Malarial
Other Names:
|
Other: Arm 2 B (cohort 2)
600 mg SJ733 administered orally once every day for three consecutive days for patients with P.falciparum
|
Anti-Malarial
Other Names:
|
Other: Arm 3 A (cohort 3)
Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.vivax
|
Anti-Malarial
Other Names:
|
Other: Arm 3 B (cohort 3)
Combination of 300 mg SJ733 with 150 mg Cobicistat administered orally once every day for three consecutive days for patients with P.falciparum
|
Anti-Malarial
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Crude Adequate Clinical and Parasitological Response (ACPR)
Time Frame: 14 days for each arm
|
Crude Adequate Clinical and Parasitological Response (ACPR) defined as the absence of microscopically determined parasitemia (thick smear).
|
14 days for each arm
|
Percent of Patients With Treatment Related Adverse Events
Time Frame: 42 days for each arm
|
Number of and seriousness of treatment related adverse events as defined in Adult Toxicity Tables
|
42 days for each arm
|
Percent of Patients With Clinically Significant Abnormal Laboratory Values
Time Frame: 42 days for each arm
|
Number of and seriousness of clinically significant abnormal laboratory values including changes from baseline in (biochemistry and hematology)
|
42 days for each arm
|
Percent of Patients With Clinically Significant Abnormal Vital Signs
Time Frame: 42 days for each arm
|
Number of and seriousness of clinically significant abnormal vital signs including changes from baseline
|
42 days for each arm
|
Percent of Patients With a Decrease in Hemoglobin (HB) > 2 g/dL From Baseline to an Absolute Value of < 5 g/dL
Time Frame: 42 days
|
Percent of patients with a decrease in hemoglobin (HB) > 2 g/dL from baseline to an absolute value of < 5 g/dL
|
42 days
|
Percent of Patients With an Absolute Neutrophil Count < 1,000/μL After Baseline
Time Frame: 42 days
|
Percent of patients with an absolute Neutrophil count < 1,000/μL after baseline
|
42 days
|
Percent of Patients Meeting Hy's Law Criteria
Time Frame: 42 days
|
Percent of patients meeting Hy's law criteria.
Hy's law criteria: (1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation of >3× the upper limit of normal (ULN); (2) total bilirubin (TBL) elevation of >2× ULN; (3) absence of initial findings of cholestasis (ie, absence of elevation of alkaline phosphatase [ALP] to >2× ULN); and (4) no other reason can be found to explain the combination of increased ALT and TBL, such as viral hepatitis A through E; other preexisting or acute liver disease; or another drug capable of causing the observed injury.
|
42 days
|
Percent of Patients With Any ALT or AST ≥ 5 x ULN
Time Frame: 42 days
|
Percent of patients with Any ALT or AST ≥ 5 x upper limit of normal (ULN)
|
42 days
|
Percent of Patients With a ny AST or ALT ≥ 3 x ULN Together With the Appearance of Fatigue, Nausea, Vomiting, Right Upper Quadrant Pain or Tenderness, Fever, Rash and/or Eosinophilia
Time Frame: 42 days
|
Percent of patients with any AST or ALT ≥ 3 x ULN together with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or eosinophilia (eosinophil percent or count above the upper limit of normal (ULN))
|
42 days
|
Percent of Patients With Persistent ALT ≥ 3 x ULN for a Period of More Than 4 Weeks.
Time Frame: 42 days
|
Percent of patients with persistent ALT ≥ 3 x ULN for a period of more than 4 weeks.
|
42 days
|
Percent of Patients With Clinical Signs of Possible Cutaneous Adverse Reactions
Time Frame: 42 days
|
Percent of patients with clinical signs of possible cutaneous adverse reactions such as dermatitis, rash, erythematous rash, macular rash, papular rash, maculo-papular rash, pruritic rash, pustular rash, vesicular rash
|
42 days
|
Percent of Patients With Clinically Significant Increases in Venous Methemoglobin Levels
Time Frame: 42 days
|
Percent of patients with clinically significant increases in venous methemoglobin levels
|
42 days
|
Percent of Patients With Significant Changes in ECG Findings
Time Frame: 42 days
|
Percent of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes or abnormalities
|
42 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug Clearance
Time Frame: 11 days for each arm
|
Drug clearance of SJ733 and its metabolite SJ506 will be reported
|
11 days for each arm
|
Number of Participants With Signs and Symptoms of Uncomplicated Malaria
Time Frame: 42 days for each arm
|
Number of participants with symptoms (including fever) or physical examination signs related to uncomplicated P. vivax or P. falciparum malaria
|
42 days for each arm
|
Parasite Clearance Time
Time Frame: 42 days for each arm
|
Time to parasite clearance as measured by microscopy
|
42 days for each arm
|
Parasite Reduction Rate
Time Frame: 0->96 h, depending upon the time required to reach lower limit of detection
|
The parasite reduction rate is calculated as the slope of the linear portion of the regression fit of natural log of average parasitemia (per microliter) versus time (in hours).
Reported slope is representative of all analyzed participants in each arm.
Slope is analyzed during time frame in which there is active reduction of parasitemia by treatment (0->96 h).
|
0->96 h, depending upon the time required to reach lower limit of detection
|
Asexual Parasite Clearance Time
Time Frame: 42 days for each arm
|
Time to clearance of asexual parasites as measured by microscopy including half life of clearance.
Clearance time represents the time at which the mean parasitemia has reached the given threshold for the arm/cohort.
For PC100, the value represents the time at which all patients have undetectable parasitemia.
|
42 days for each arm
|
Percent Change in Asexual Parasites From Baseline
Time Frame: 42 days
|
Percentage change of asexual parasites as determined by microscopy, relative to baseline at the specified times.
The value represents the average parasitemia in the arm/cohort at the given time (per microliter) versus time (in hours) compared to the average parasitemia at T0. Reported reduction is representative of all analyzed participants in each arm.
|
42 days
|
Area Under the Plasma Concentration-time Curve (AUC)
Time Frame: 11 days for each arm
|
AUC of SJ733 and its metabolite SJ506 will be reported
|
11 days for each arm
|
Maximum Plasma Drug Concentration (Cmax)
Time Frame: 11 days for each arm
|
Cmax of SJ733 and its metabolite SJ506 will be reported
|
11 days for each arm
|
Time to Reach Maximum Plasma Concentration (Tmax)
Time Frame: 11 days for each arm
|
Time to reach maximum plasma concentration (Tmax) of SJ733 will be reported
|
11 days for each arm
|
Crude Adequate Clinical and Parasitological Response (ACPR) at Days 28, 35, and 42
Time Frame: 42 days for each arm
|
Crude Adequate Clinical and Parasitological Response (ACPR) at Days 28, 35, and 42 as measured by microscopy.
|
42 days for each arm
|
Time to Recurrence of Malaria Infection
Time Frame: 42 days for each arm
|
Time to recurrence of either P. vivax or P. falciparum malaria as measured by signs and symptoms or malaria and microscopy
|
42 days for each arm
|
Fever Clearance Time
Time Frame: 42 days for each arm
|
Time from baseline to the first of two consecutive post-dose auxiliary temperature measurements < 37.5 C obtained within an interval of 4 to 24 hours of each other
|
42 days for each arm
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Crude Adequate Clinical and Parasitological Response (ACPR), PCR Adjusted, at Days 7, 14, 28, 35, and 42
Time Frame: 42 days for each arm
|
Crude Adequate Clinical and Parasitological Response (ACPR) as adjusted by quantitative PCR of parasite DNA at Days 7, 14, 28, 35, and 42
|
42 days for each arm
|
Time to Recurrence of Malaria Infection, PCR Adjusted
Time Frame: 42 days for each arm
|
Time to recurrence of either P. vivax or P. falciparum malaria as measured by PCR
|
42 days for each arm
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alejandro L Cuentas, MD, PhD, Asociacion Civil Selva Amazonica (ACSA)
Publications and helpful links
General Publications
- Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gomez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martinez MS, Miller G, Rodriguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62. doi: 10.1073/pnas.1414221111. Epub 2014 Dec 1. Erratum In: Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5764.
- Gaur AH, McCarthy JS, Panetta JC, Dallas RH, Woodford J, Tang L, Smith AM, Stewart TB, Branum KC, Freeman BB 3rd, Patel ND, John E, Chalon S, Ost S, Heine RN, Richardson JL, Christensen R, Flynn PM, Van Gessel Y, Mitasev B, Mohrle JJ, Gusovsky F, Bebrevska L, Guy RK. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infect Dis. 2020 Aug;20(8):964-975. doi: 10.1016/S1473-3099(19)30611-5. Epub 2020 Apr 8.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 53333
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria, Falciparum
-
University of OxfordTerminatedP. Falciparum MalariaThailand
-
National Institute of Allergy and Infectious Diseases...CompletedAccute Falciparum MalariaMali
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces...CompletedAzithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in BangladeshUncomplicated Falciparum MalariaBangladesh
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health...UnknownUncomplicated Falciparum MalariaMyanmar
-
University of OxfordNanyang Technological University; Texas Biomedical Research InstituteCompletedP. Falciparum Malaria | P. Falciparum Malaria Mixed InfectionThailand
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Universidad Nacional de ColombiaSanofi Pasteur, a Sanofi CompanyCompleted
-
National Institute for Medical Research, TanzaniaWorld Health Organization; Muhimbili University of Health and Allied SciencesCompletedUncomplicated Falciparum MalariaTanzania
-
University of OxfordCompletedSevere Falciparum MalariaBangladesh
-
Heidelberg UniversityCompletedUncomplicated Falciparum MalariaBurkina Faso
Clinical Trials on (+)-SJ000557733 (SJ733)
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...CompletedPlasmodium Falciparum MalariaAustralia
-
St. Jude Children's Research HospitalEisai Inc.; Medicines for Malaria Venture; Global Health Innovative Technology...CompletedMalariaUnited States